Trinity Life Sciences, a global leader in life sciences solutions, has indicated that the 2022 National Reimbursement Drug List (NRDL) in China presents promising opportunities for innovative drugs. The company’s white paper titled “2022 NRDL Pricing Implementation and Access Outcomes in China” analyses the NRDL update, reflecting the rapid evolution of China’s healthcare industry and its commitment to balance cost sustainability while providing broad access to innovative medicines.
The NRDL has been a critical market access pathway in China since 2017. The 2022 NRDL update, which will take effect from March 2023, reveals pricing and access trends that are significant for reimbursement in China. The white paper identifies five major changes in the NRDL aimed at optimizing the review process. These changes include higher negotiation success rates, consistent price discounts, emphasis on innovative therapy inclusion, increasing multinational manufacturer presence, and expanded coverage in a variety of therapeutic areas.
China’s Healthcare Market: Insights from the 2022 NRDL Update on Innovative Drugs
The focus of the 2022 NRDL is primarily on oncology, rare diseases, and chronic diseases. Notably, oncology drugs received an average discount of 58%, while rare disease drugs saw lower discounts compared to 2021. While regular disease drugs face significant price discounting, they can achieve premium pricing with robust clinical data.
This update stresses the necessity for manufacturers to consider China in their global commercialization strategies, as the country’s healthcare outlook promises improved pricing and access opportunities for drugs backed by solid clinical evidence. Trinity Life Sciences provides yearly guidance on the NRDL to assist life sciences executives in navigating China’s changing access landscape. The implications of the 2022 NRDL update are further explored in an on-demand webinar.
The 2022 NRDL update in China highlights the country’s commitment to providing broad access to innovative medicines while maintaining cost sustainability. The list primarily focuses on oncology, rare diseases, and chronic diseases, offering promising opportunities for innovative drugs. The update necessitates that manufacturers consider China in their global commercialization strategies, due to the country’s promising healthcare outlook that allows for better pricing and access opportunities for drugs with strong clinical evidence.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
